Food and Drug Administration (FDA) for use of the company’s next generation mammography computer-aided detection (CAD) platform, PowerLook Advanced Mammography Platform (AMP)TM, with Digital CAD for Philips’ MicroDose Full-Field Digital Mammography System.ICAD, Inc. Is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. ICAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT).

ICAD’s solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. For more information, call (877) iCADnow.In 2005, the Boston Scientific Corporation received FDA approval of a Humanitarian. For treatment of ICAD with intracranial angioplasty and stenting.'Additionally, seamless integration of iCADs product with our PACS system will improve the efficiency of our reading and our overall digital workflow.' Since Fujifilm received FDA approval for FCRm in July 2006, the company has enjoyed record sales in the U.S. Market, enabling the conversion to digital of nearly 500 mammography exam rooms.Some companies claim to have correspondence with the FDA about using diverse datasets, such as AI breast imaging detection provider iCAD. NASHUA, N.H.-(BUSINESS WIRE)- iCAD, Inc.

The suspicious areas are naturally blended onto a 2D synthetic image to provide radiologists with a single enhanced image that is used to more efficiently navigate the large tomosynthesis data set.'iCAD has taken a refreshing new approach to computer aided detection. PowerLook Tomo Detection improves radiologists' efficiency by automatically analyzing each tomosynthesis plane and identifying suspicious areas. With the potential to greatly improve clinical workflow and patient care in the years ahead.'2D digital mammography typically produces four images per exam while digital breast 3D tomosynthesis can produce hundreds of images, significantly increasing exam interpretation time for radiologists. 'FDA approval of PowerLook Tomo Detection is a significant milestone for the Company and we are positioned to rapidly advance our commercial plan for this innovative technology in the U.S. And abroad, iCAD remains committed to delivering innovative solutions that help radiologists be more efficient and confident when reading tomosynthesis exams,' said Ken Ferry, CEO of iCAD. PowerLook Tomo Detection is a first-of-its-kind, concurrent-read computer aided detection solution for digital breast 3D tomosynthesis and is the latest innovation available on the PowerLook® Breast Health Solutions platform.'As the use of 3D mammography continues to grow in the U.S.

Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The words 'believe', 'demonstrate', 'intend', 'expect', 'would', 'could', 'consider', 'project', 'estimate', 'will', 'continue', 'anticipate', 'likely', 'seek', and similar expressions identify forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company and other risks detailed in the Company's filings with the Securities and Exchange Commission. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For more information, visit or 'Safe Harbor' Statement under the Private Securities Litigation Reform Act of 1995Certain statements contained in this News Release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. ICAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.

Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.3. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit2. Lynn Granito, view the original version on PR Newswire, visit: 1. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at and on the SEC's website at.

Cochlear Americas Receives FDA Approval for the First and Only Ear Level Accessory for Waterproof Hearing with Cochlear Implants9. Breathe Technologies Sleep System Receives FDA Clearance8. Inostics Blood-based Mutation Testing Receives CLIA Certification7. BioElectronics Receives Working Capital Infusion6. Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System5. Announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases4.

Prime Therapeutics specialty pharmacy receives URAC accreditation11.

Icad Fda Approval